- Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapiesT G Woodworth
Pfizer Groton R and D, Groton, CT, USA
J Rheumatol 28:1163-9. 2001..Before this tool is widely accepted, its validity, consistency, and feasibility need to be assessed in clinical trials...